Clinical Trials

The MDHAQ/RAPID3 has been successfully used in numerous studies with positive results. Some of the clinical trials that have used the MDHAQ/RAPID3 include:

• A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome.  (Protocol IM101-280)
• Tocilizumab for the Treatment of Behcet's Syndrome (Protocol ML27874)
• The Health Log: A Randomized Clinical Trial.(Protocl 2013P000973)
• A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects (PREDICT) (Protocol RA0064)
• Real-world Clinical Efficacy of Abatacept in the T3 Data Registry (Protocol IM101-322)
• A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor (Protocol MA25522)
• A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs) (Protocol ML22533)
• TIV and High Dose TIV in Subjects With Rheumatoid Arthritis (Protocol 10-0076)
• Perioperative Flare in RA: Characterization of Clinical and Biological Features (Periop Flare) (Protocol 13146)
• Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion (Protocol EFC12368)